Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- PMDA Unveils New International Strategy
June 30, 2015
- MHLW Global Strategy Aims at Regulatory Shortcut for Japan-OK’ed Drugs
June 29, 2015
- Drug Pricing Tomorrow: MHLW’s Jo Says Price-Maintenance Premium Crucial as Post-Launch Reward for Innovation
June 29, 2015
- MHLW Approves Additional Indications for Radicut and Other Products
June 29, 2015
- 8 Members Exit Pharmaceutical Affairs Council
June 26, 2015
- LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
- Problems at Kaketsuken Remained Undetected Despite 21 On-Site Inspections over 10-Year Period: PMDA
June 26, 2015
- Univ. of Tokyo Prof. Tanabe Elected as Chuikyo Chairman
June 25, 2015
- HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
- AMED Initiates “Middle Molecule Drug Discovery” Project; Aims to Out-License Lead Compounds to Drug Makers
June 25, 2015
- Panel Begins Discussions on Revising Basic Guidelines for Measures against Hepatitis
June 25, 2015
- Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
- Kaketsuken Likely to Face Administrative Penalty over GMP Violation
June 24, 2015
- LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
- PMDA Beats Its Targets for Overall Review Time in FY2014
June 24, 2015
- Draft Growth Strategy Embraces Clinical Development Infrastructure, Drops Numerical Target for Sakigake System
June 23, 2015
- 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
- PMDA, AMED Plan to Enter Partnership Agreement; Share Information to Promote Commercialization of Seeds
June 23, 2015
- Editor’s Pick: Five Healthcare News Headlines for June 8 - June 21
June 22, 2015
- AMED’s Screening Consortium “Won’t Harm Companies”: Official
June 22, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…